Skip to main content

Dental Pain

5
Pipeline Programs
7
Companies
7
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
3
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Alkermes
AlkermesDUBLIN 4, Ireland
2 programs
1
1
ketorolacPhase 3
N1539Phase 21 trial
Active Trials
NCT00945763Completed230Est. Nov 2009
Lotus Pharmaceuticals
Lotus PharmaceuticalsTaiwan - Taipei
1 program
1
Bupivacaine liposomePhase 31 trial
Active Trials
NCT02517905Completed166Est. Jan 2016
ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
GW406381Phase 3
Pfizer
PfizerNEW YORK, NY
1 program
1
ARRY-371797, p38 inhibitor; oralPhase 21 trial
Active Trials
NCT00542035Completed103Est. Feb 2008
IBSA Institut Biochimique
IBSA Institut BiochimiqueSwitzerland - Lugano-Pazzallo
2 programs
Diclofenac HPBCDPHASE_31 trial
Diclofenac HPBCD s.c. 75mg/mlPHASE_31 trial
Active Trials
NCT00942448Completed306Est. Apr 2010
NCT00943098Completed142Est. May 2010
Xenon Pharmaceuticals
1 program
XPF-001PHASE_21 trial
Active Trials
NCT00954356Completed61Est. Dec 2009
GSK
GSKLONDON, United Kingdom
1 program
GW406381PHASE_31 trial
Active Trials
NCT00114049Completed300Est. Apr 2005

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Lotus PharmaceuticalsBupivacaine liposome
IBSA Institut BiochimiqueDiclofenac HPBCD
IBSA Institut BiochimiqueDiclofenac HPBCD s.c. 75mg/ml
GSKGW406381
Xenon PharmaceuticalsXPF-001
AlkermesN1539
PfizerARRY-371797, p38 inhibitor; oral

Clinical Trials (7)

Total enrollment: 1,308 patients across 7 trials

NCT02517905Lotus PharmaceuticalsBupivacaine liposome

Evaluation of EXPAREL for Prolonged Postsurgical Analgesia in Subjects Undergoing Third Molar Extraction

Start: Aug 2015Est. completion: Jan 2016166 patients
Phase 3Completed
NCT00942448IBSA Institut BiochimiqueDiclofenac HPBCD

Evaluation of the Efficacy and Safety of Diclofenac HPBCD 25, 50 mg/ml in the Treatment of Post-surgical Pain Following Dental Surgery

Start: Sep 2009Est. completion: Apr 2010306 patients
Phase 3Completed
NCT00943098IBSA Institut BiochimiqueDiclofenac HPBCD s.c. 75mg/ml

Evaluation of the Efficacy and Safety of Diclofenac HPBCD 75mg/ml in Treatment of Pain Following Dental Surgery

Start: Sep 2009Est. completion: May 2010142 patients
Phase 3Completed
NCT00114049GSKGW406381

Dental Pain (Following Third Molar Tooth Extraction) Study

Start: Dec 2004Est. completion: Apr 2005300 patients
Phase 3Completed
NCT00954356Xenon PharmaceuticalsXPF-001

Safety and Efficacy Study of XPF-001 to Treat Pain Following Wisdom Tooth Extraction

Start: Sep 2009Est. completion: Dec 200961 patients
Phase 2Completed
NCT00945763AlkermesN1539

Single Dose Study of N1539 in the Treatment of Pain Secondary to Dental Impaction Surgery

Start: Jul 2009Est. completion: Nov 2009230 patients
Phase 2Completed
NCT00542035PfizerARRY-371797, p38 inhibitor; oral

A Study of ARRY-371797 in Subjects Undergoing Third Molar Extraction

Start: Nov 2007Est. completion: Feb 2008103 patients
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.